Notably, we identified an actionable mutation, IDH1 p.R132S, in 6.9% of SFTs, and observed high PD-L1 expression in tumor or immune cells in 24.4% of cases, suggesting potential benefits of combination of immune therapy and targeted therapy. Here, CD274 is linked to neoplasm.